You are here:  Home     August 25, 2016


National Pediatric Sleep Groups   
News and activities from Pediatric Sleep Groups all over the world

Pediatric Sleep


IPSA suggestions   
help us to make IPSA more complete and useful, send information about pediatric sleep activities in Your country.

After the mail ballot we have the results of the new board that is composed by:
President Christian Guilleminault (USA)
Past President Oliviero Bruni (Italy)
Vice President Patricia Franco (France)
Secretary Rosemary Horne (Australia)
Director Rosana Alves (Brazil)
Director Sarah Biggs (Australia)
Director Ron Chervin (USA)
Director Paul Gringras (UK)
Director Daniel Ng (Hong Kong)
Director Judith Owens (USA)
Director Teresa Paiva (Portugal)  


IPSA Congress 2016 - Taiwan March 11-13, 2016
Dear Friends, On behalf of the organizing committee, we are extremely happy to invite you to participate in the
IV International Pediatric Sleep Association Congress (IPSA 2016) which will be held on March 11-13, 2016, in Taipei International Convention Center, located in the heart of Taipei, Taiwan.

We sincerely hope the beauty of our city and the theme of our conference will attract you all. The IPSA 2016 serves as a premier event on the international calendar of pediatric sleep bringing together physicians, educators, basic scientists, sleep technician and clinical investigators from hospitals, industry, and academia to present and share the latest cutting-edge research results and innovative solutions in the related fields. We believe you will have a fruitful and enjoyable time during your stay in Taipei based on our solid program and the hospitality of Taipei, Taiwan aka “Formosa”.(“beautiful in Portuguese”) island, as used by the Portuguese mariners centuries ago to describe Taiwan Look forward to seeing you in Taipei, Taiwan in 2016! Best Regards, Dr. Yu-Shu Huang, Chair of IPSA 2016 and Local Organizer Dr. Daniel KK Ng, Co-Chair of IPSA 2016 Dr. Oliviero Bruni, President of IPSA Dr. Chia-Mo Lin, President of Taiwan Society of Sleep Medicine   read more...

IPSA Congress 2014 - Porto Alegre - Brazil - Sunday, September 29, 2013

It is my pleasure to present the
III Congress of the International Pediatric Sleep Association (IPSA) - Porto Alegre (Brazil) 3-5 December 2014.

The importance of sleep for health, learning and psychomotor development in infancy, childhood and adolescence has been emphasized in the pediatric research in the last two decades and it has become more and more evident that ensuring a good sleep during development is of key importance for a later healthy life.
The IPSA Congress is an influential forum for sleep practitioners from around the world to network and exchange views, whilst learning from world-class researchers about the latest scientific and clinical developments in the field.
The success of the last two Congresses in Rome 2010 and Manchester 2012 has highlighted the magnitude of Pediatric Sleep Medicine in the scientific community and we hope that the 2014 Congress will provide a perfect balance between didactic and practical needs, in order to provide the technical knowhow and up-to-date knowledge that will enable participants to improve their practice.
As traditional for IPSA, the most renowned International opinion leaders in the field of Pediatric Sleep Medicine speakers will join the Congress and will highlight the recent significant advances in both basic science and clinical sleep medicine during development.
I hope that the world paediatric sleep community will gather together in the lively city of Porto Alegre to celebrate the best clinical practice and the latest advances in Pediatric Sleep Medicine.

Oliviero Bruni
President of the International Pediatric Sleep Association


IPSA Congress 5-7 december 2012 - Manchester City (UK)

IPSA Congress 5-7th December 2012 - Manchester (UK)  


IPSA 2010 - Abstract Book




Guia SAOS Infantil Espanola

New guidelines on the diagnosis and treatment of OSA in children published by the Spanish Pediatric Sleep Group. (available only in Spanish)



[PageLinks]     TIP: Press shift while clicking on the article to open in a new window.

Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma.

Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma.

N Engl J Med. 2016 Aug 18;375(7):619-30

Authors: Sheehan WJ, Mauger DT, Paul IM, Moy JN, Boehmer SJ, Szefler SJ, Fitzpatrick AM, Jackson DJ, Bacharier LB, Cabana MD, Covar R, Holguin F, Lemanske RF, Martinez FD, Pongracic JA, Beigelman A, Baxi SN, Benson M, Blake K, Chmiel JF, Daines CL, Daines MO, Gaffin JM, Gentile DA, Gower WA, Israel E, Kumar HV, Lang JE, Lazarus SC, Lima JJ, Ly N, Marbin J, Morgan WJ, Myers RE, Olin JT, Peters SP, Raissy HH, Robison RG, Ross K, Sorkness CA, Thyne SM, Wechsler ME, Phipatanakul W, NIH/NHLBI AsthmaNet

BACKGROUND: Studies have suggested an association between frequent acetaminophen use and asthma-related complications among children, leading some physicians to recommend that acetaminophen be avoided in children with asthma; however, appropriately designed trials evaluating this association in children are lacking.
METHODS: In a multicenter, prospective, randomized, double-blind, parallel-group trial, we enrolled 300 children (age range, 12 to 59 months) with mild persistent asthma and assigned them to receive either acetaminophen or ibuprofen when needed for the alleviation of fever or pain over the course of 48 weeks. The primary outcome was the number of asthma exacerbations that led to treatment with systemic glucocorticoids. Children in both groups received standardized asthma-controller therapies that were used in a simultaneous, factorially linked trial.
RESULTS: Participants received a median of 5.5 doses (interquartile range, 1.0 to 15.0) of trial medication; there was no significant between-group difference in the median number of doses received (P=0.47). The number of asthma exacerbations did not differ significantly between the two groups, with a mean of 0.81 per participant with acetaminophen and 0.87 per participant with ibuprofen over 46 weeks of follow-up (relative rate of asthma exacerbations in the acetaminophen group vs. the ibuprofen group, 0.94; 95% confidence interval, 0.69 to 1.28; P=0.67). In the acetaminophen group, 49% of participants had at least one asthma exacerbation and 21% had at least two, as compared with 47% and 24%, respectively, in the ibuprofen group. Similarly, no significant differences were detected between acetaminophen and ibuprofen with respect to the percentage of asthma-control days (85.8% and 86.8%, respectively; P=0.50), use of an albuterol rescue inhaler (2.8 and 3.0 inhalations per week, respectively; P=0.69), unscheduled health care utilization for asthma (0.75 and 0.76 episodes per participant, respectively; P=0.94), or adverse events.
CONCLUSIONS: Among young children with mild persistent asthma, as-needed use of acetaminophen was not shown to be associated with a higher incidence of asthma exacerbations or worse asthma control than was as-needed use of ibuprofen. (Funded by the National Institutes of Health; AVICA number, NCT01606319.).

PMID: 27532828 [PubMed - indexed for MEDLINE]

Sleep-Disordered Breathing in Adolescents and Younger Adults: A Representative Population-Based Survey in Chile.
Related Articles

Sleep-Disordered Breathing in Adolescents and Younger Adults: A Representative Population-Based Survey in Chile.

Chest. 2016 Apr;149(4):981-90

Authors: Brockmann PE, Damiani F, Gozal D

BACKGROUND: Prevalence and potential risk contributors of sleep-disordered breathing (SDB) in adolescents and younger adults remain unclear. We hypothesized that SDB prevalence in younger Hispanic adults is higher than the limited evidence indicates.
METHODS: This is a population-based study of Hispanic subjects surveyed as part of the Chilean National Health Survey database. For this study, only subjects aged 15 to 40 years were included. Sleep and demographic questionnaires were used to assess SDB prevalence and its risk factors. Anthropometric measurements were performed in each subject. Prevalence was calculated for each SDB-related symptom. A regression model was constructed to investigate demographic risk factors of SDB.
RESULTS: A total of 2,147 subjects were included. Mean age (± SD) was 27.2 ± 7.2 years, n = 899 (42%) were men. Habitual snoring was highly prevalent, with an average of 53.8% in men and 38.3% in women. Snoring, witnessed apneas, and daytime somnolence increased continuously with age, with an abnormal SDB questionnaire score detected in 2.5%. Reported sleep duration was 7.61 ± 1.67 hours during weekdays and 8.27 ± 2.11 hours during weekends. Snoring frequency was significantly higher in men than women at nearly all age groups, and an adjusted regression model (OR [95% CI]) identified male sex (2 [1.6-2.5]; P < .001) and BMI (1.08 [1.03-1.12]; P < .001) as independent risk factors for snoring.
CONCLUSION: The risk of SDB is highly prevalent in younger adults, even in females, and increases with age and BMI. The high prevalence and low awareness justify active screening and treatment of SDB in this population.

PMID: 26539784 [PubMed - indexed for MEDLINE]

Impact of Adenotonsillectomy on Insulin Resistance and Lipoprotein Profile in Nonobese and Obese Children.
Related Articles

Impact of Adenotonsillectomy on Insulin Resistance and Lipoprotein Profile in Nonobese and Obese Children.

Chest. 2016 Apr;149(4):999-1010

Authors: Koren D, Gozal D, Bhattacharjee R, Philby MF, Kheirandish-Gozal L

BACKGROUND: OSA associates with insulin resistance (IR), hyperglycemia, and dyslipidemia consistently in adults, but inconsistently in children. We set out to quantify the impact of OSA treatment upon obesity and metabolic outcomes and thus assess causality.
METHODS: Sixty-nine children with OSA; mean age, 5.9 years (range, 3-12.6); 55% boys; and 68% nonobese (NOB) underwent baseline overnight polysomnography, anthropometric and metabolic measurements, adenotonsillectomy (T&A), and follow-up testing a mean 7.9 months (range, 2-20) later.
RESULTS: Fifty-three children (77% of study cohort; 91% of obese children) had residual OSA (apnea-hypopnea index > 1 event/h) post-T&A. Fasting plasma insulin (FPI, 14.4 ± 9.4 → 12.6 ± 9.7 μIU/mL, P = .008), homeostasis model assessment-IR (3.05 ± 2.13 → 2.62 ± 2.22, P = .005), and high-density lipoprotein (HDL) (51.0 ± 12.9 → 56.5 ± 14.4 mg/dL, P = .007) improved despite increased BMI z score (1.43 ± 0.78 → 1.52 ± 0.62, P = .001); changes did not differ significantly between sexes or NOB and obese participants; however, post-T&A BMI z score rather than apnea-hypopnea index was the main predictor of levels of follow-up FPI, HDL, and other metabolic parameters. Higher baseline FPI and BMI-z predicted likelihood of residual OSA; conversely, on regression analysis, follow-up IR, HDL, and triglycerides were predicted by BMI z score, not residual OSA.
CONCLUSIONS: T&A improved IR and HDL, and residual OSA is predicted by baseline FPI and BMI z score, indicating a causal relationship; however, following T&A, residual metabolic dysfunction related to underlying adiposity rather than remaining sleep-disordered breathing. Finally, T&A cured OSA in < 25% of all children and only 10% of obese children; post-T&A polysomnography is indicated to assess which children still require treatment.

PMID: 26447773 [PubMed - indexed for MEDLINE]


Join IPSA. It's free!!!   
Just add Your data to the membership module  

Upcoming Meetings   


Home|IPSA Mission|Board|Bylaws|Contact IPSA|Membership|Site Map
Copyright (c) 2016 IPSA Terms Of Use Privacy Statement